[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA, ALLNA 2008 Conference: Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer; 2010 Jul 1;54(7):872-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
  • One of the challenges of incorporating molecularly targeted drugs into multi-agent chemotherapy (backbone) regimens is defining dose-limiting toxicities (DLTs) of the targeted agent against the background of toxicities of the backbone regimen.
  • An international panel of 22 pediatric acute lymphocytic leukemia (ALL) experts addressed this issue (www.ALLNA.org).
  • (1) how toxicities can be best defined, assessed, and attributed; and (2) how effective dosing of new agents incorporated into multi-agent ALL clinical trials can be safely established in the face of disease- and therapy-related systemic toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1126-32 [19228717.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Sep-Oct;20(5):431-8 [9787315.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):73-81 [18324639.001]
  • [Cites] Curr Drug Targets. 2007 Jun;8(6):703-14 [17584026.001]
  • [Cites] Curr Drug Targets. 2007 Jun;8(6):751-9 [17584030.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6 Suppl 5):S13-20 [18086342.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):190-5 [18182661.001]
  • [Cites] Paediatr Drugs. 2008;10(2):85-92 [18345718.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • (PMID = 20127846.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113775-04; United States / NCI NIH HHS / CA / K23 CA111728; United States / NCI NIH HHS / CA / K23 CA113775; United States / NCI NIH HHS / CA / K23 CA113775-04
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 14
  • [Other-IDs] NLM/ NIHMS163748; NLM/ PMC2857540
  •  go-up   go-down


2. Rice SC, Vacek P, Homans AH, Messier T, Rivers J, Kendall H, Finette BA: Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia. Cancer Res; 2004 Jul 1;64(13):4464-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia.
  • The survival rates of children treated for cancer have dramatically increased after the development of standardized multiple-modality treatment protocols.
  • As a result, there is a rapidly growing population of pediatric cancer survivors in which the long-term genotoxic effects of chemotherapeutic intervention is unknown.
  • To study the genotoxic effects of antineoplastic treatment in children, we performed a comparative analysis of the changes in the frequency of somatic mutations (Mfs) at the hypoxanthine-guanine phosphoribosyltransferase (HPRT)-reporter gene in children treated for acute lymphocytic leukemia (ALL).
  • We measured HPRT Mfs from 130 peripheral blood samples from 45 children with ALL (13, low risk; 22, standard risk; and 10, high risk) from the time of diagnosis, as well as during and after the completion of therapy.
  • We observed a significant increase in mean HPRT Mfs during each phase of therapy (diagnosis, 1.4 x 10(-6); consolidation, 52.1 x 10(-6); maintenance, 93.2 x 10(-6); and off-therapy, 271.7 x 10(-6)) that were independent of the risk group treatment protocol used.
  • This 200-fold increase in mean somatic Mf remained elevated years after the completion of therapy.
  • We did not observe a significant difference in the genotoxicity of each risk group treatment modality despite differences in the compositional and clinical toxicity associated with these treatment protocols.
  • These findings suggest that combination chemotherapy used to treat children with ALL is quite genotoxic, resulting in an increased somatic mutational load that may result in an elevated risk for the development of multi-factorial diseases, in particular second malignancies.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15231655.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 P20RR16462; United States / NCI NIH HHS / CA / 1K01CA77737; United States / NCI NIH HHS / CA / 1R01CA09094013; United States / NICHD NIH HHS / HD / 1R29HD35309; United States / NCI NIH HHS / CA / P30CA22435
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


3. Kendall HE, Vacek PM, Rivers JL, Rice SC, Messier TL, Finette BA: Analysis of genetic alterations and clonal proliferation in children treated for acute lymphocytic leukemia. Cancer Res; 2006 Sep 1;66(17):8455-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of genetic alterations and clonal proliferation in children treated for acute lymphocytic leukemia.
  • The development of risk-directed treatment protocols over the last 25 years has resulted in an increase in the survival rates of children treated for cancer.
  • As a consequence, there is a growing population of pediatric cancer survivors in which the long-term genotoxic effects of chemotherapy is unknown.
  • We previously reported that children treated for acute lymphocytic leukemia have significantly elevated somatic mutant frequencies at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene in their peripheral T cells.
  • To understand the molecular etiology of the increase in mutant frequencies following chemotherapy, we investigated the HPRT mutation spectra and the extent of clonal proliferation in 562 HPRT T cell mutant isolates of 87 blood samples from 47 subjects at diagnosis, during chemotherapy, and postchemotherapy.
  • We observed a significant increase in the proportion of CpG transitions following treatment (13.6-23.3%) compared with healthy controls (4.0%) and a significant decrease in V(D)J-mediated deletions following treatment (0-6.8%) compared with healthy controls (17.0%).
  • There was also a significant change in the class type percentage of V(D)J-mediated HPRT deletions following treatment.
  • These data indicate that unique genetic alterations and extensive clonal proliferation are occurring in children following treatment for acute lymphocytic leukemia that may influence long-term risks for multifactorial diseases, including secondary cancers.
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cloning, Molecular. Female. Humans. Male. Polymerase Chain Reaction. Receptors, Antigen, T-Cell / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951156.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K01CA77737; United States / NCI NIH HHS / CA / 1R01CA09094013; United States / NICHD NIH HHS / HD / 1R29HD35309; United States / NCI NIH HHS / CA / P30CA22435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Antigen, T-Cell; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


Advertisement
4. Sorich MJ, Pottier N, Pei D, Yang W, Kager L, Stocco G, Cheng C, Panetta JC, Pui CH, Relling MV, Cheok MH, Evans WE: In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med; 2008 Apr 15;5(4):e83
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
  • BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients.
  • Nevertheless, drug resistance is the major cause of treatment failure in children with ALL.
  • The drug methotrexate (MTX), which is widely used to treat many human cancers, is used in essentially all treatment protocols worldwide for newly diagnosed ALL.
  • Although MTX has been extensively studied for many years, relatively little is known about mechanisms of de novo resistance in primary cancer cells, including leukemia cells.
  • METHODS AND FINDINGS: We utilized measures of decreased circulating leukemia cells of 293 newly diagnosed children after initial "up-front" in vivo MTX treatment (1 g/m(2)) to elucidate interpatient differences in the antileukemic effects of MTX.
  • We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating leukemia cells after initial in vivo treatment with MTX.
  • CONCLUSIONS: Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL.
  • TRIAL REGISTRATIONS: Total XV, Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia, http://www.ClinicalTrials.gov (NCT00137111); Total XIIIBH, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Intermediate or High Risk of Treatment Failure (NCI-T93-0101D); Total XIIIBL, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Lower Risk of Treatment Failure (NCI-T93-0103D).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Profiling. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplastic Cells, Circulating. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):93-9 [14693814.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95 [12972803.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Vitam Horm. 2003;66:403-56 [12852262.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):775-81 [12618889.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1240-7 [12149204.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2423-9 [12114448.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1832-9 [16936229.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Biochem Pharmacol. 1999 Aug 15;58(4):539-55 [10413291.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1067-74 [9920857.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5638-44 [2458828.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1449-63 [2207320.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1041-8 [8793930.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 18;88(18):1255-6 [8797761.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):20-4 [9915496.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Haematologica. 2001 Feb;86(2):121-7 [11224479.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • (PMID = 18416598.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00137111
  • [Grant] United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R01 CA51001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2292747
  •  go-up   go-down


5. Dłuzniewska A, Balwierz W, Balcerska A, Chybicka A, Dobaczewski G, Kowalczyk J, Krenke K, Lewandowska D, Malinowska I, Matysiak M, Mikołajczyk M, Niedźwiedzki M, Rokicka-Milewska R, Sońta-Jakimczyk D, Stefaniak J, Styczyński J, Tomaszewska R, Wachowiak J, Wysocki M: [Efficacy of idarubicin in the treatment of childhood acute non-lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group]. Przegl Lek; 2003;60 Suppl 5:17-21
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of idarubicin in the treatment of childhood acute non-lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group].
  • Results of treatment of childhood ANLL remained unsatisfactory for a long time, and introduction of a new drug seemed justified as the EFS achieved in this disease between 1993-97 was 42%.
  • In 1998 a new protocol containing idarubicine in dose 12 mg/m2 (each dose regardless of treatment phase) was introduced.
  • Between 1998 and 2001, 137 children with ANLL were referred to nine participating centers of PPLLSG.
  • Better new treatment methods are required in HRG.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Idarubicin / therapeutic use. Leukemia, Myeloid, Acute / drug therapy


6. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC: A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer; 2009 Dec;53(6):978-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.
  • BACKGROUND: Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis.
  • Campath-1H was initially administered as an intravenous infusion over 2 hr, five times per week for 1 week, then three times per week for three additional weeks.
  • Patients with stable disease or better on day 29 could continue on to combination therapy with Campath-1H, methotrexate, and 6-mercaptopurine for two additional cycles.
  • No patients received combination therapy.
  • Serum Campath-1H concentrations appeared to be somewhat lower in children with ALL compared with adult patients with chronic lymphocytic leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2245-7 [11877305.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] J Clin Pathol. 2003 Apr;56(4):249-53 [12663634.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):205-19 [15101704.001]
  • [Cites] Blood. 2004 Aug 15;104(4):948-55 [15090452.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7024-31 [16145065.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2337-42 [16618945.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2645-51 [16688777.001]
  • [Cites] Transpl Int. 2006 Sep;19(9):705-14 [16918530.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Ann Oncol. 2007 Jan;18 Suppl 1:i3-i8 [17311819.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3644-53 [17530018.001]
  • [Cites] J Neurol Sci. 2007 Aug 15;259(1-2):128-32 [17362994.001]
  • [Cites] Br J Clin Pharmacol. 2007 Sep;64(3):278-91 [17506867.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] J Immunol Methods. 2002 Feb 1;260(1-2):285-302 [11792397.001]
  • (PMID = 19637330.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097452-09; United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U-01 CA97452; United States / NCI NIH HHS / CA / CA097452-09; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U-10 CA98543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ NIHMS144404; NLM/ PMC3120889
  •  go-up   go-down


7. Sgarbieri UR, Fisberg M, Tone LG, Latorre Mdo R: Nutritional assessment and serum zinc and copper concentration among children with acute lymphocytic leukemia: a longitudinal study. Sao Paulo Med J; 2006 Nov 7;124(6):316-20
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional assessment and serum zinc and copper concentration among children with acute lymphocytic leukemia: a longitudinal study.
  • CONTEXT AND OBJECTIVE: When undergoing chemotherapy and/or radiotherapy, children with acute lymphocytic leukemia may present important nutritional disorders because of the gastrointestinal toxicity of most chemotherapy agents or the effects of radiation on the organism.
  • The present study aimed to follow anthropometric parameters and serum levels of zinc and copper in a group of children under treatment for acute lymphocytic leukemia.
  • DESIGN AND SETTING: Longitudinal study, at the Pediatric Section of Hospital das Clínicas, Ribeirão Preto, Brazil.
  • METHODS: Forty-five children with acute lymphocytic leukemia were studied.
  • Anthropometric parameters such as weight and height and the daily intakes and serum levels of copper and zinc were recorded at diagnosis and during the treatment.
  • RESULTS: During the initial phase of the treatment, there was an increase in energy intake accompanied by weight gain.
  • However, during the later phases of treatment there was a reduction in energy intake with accompanying weight loss.
  • Decreased growth rate during treatment was more pronounced in children with high-risk acute lymphocytic leukemia, probably due to radiation therapy.
  • Serum zinc levels remained basically unaltered during the treatment, whereas copper levels decreased dramatically with the beginning of treatment.
  • CONCLUSIONS: The treatment given to children with acute lymphocytic leukemia has an important effect on their linear growth rate and nutritional status, and also on their serum copper levels.
  • [MeSH-major] Copper / blood. Growth / drug effects. Nutrition Assessment. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Zinc / blood
  • [MeSH-minor] Anthropometry. Antineoplastic Combined Chemotherapy Protocols. Body Size / physiology. Child. Child, Preschool. Energy Intake. Female. Humans. Infant. Longitudinal Studies. Male. Nutritional Status. Risk Factors. Time Factors

  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322951.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 789U1901C5 / Copper; J41CSQ7QDS / Zinc
  •  go-up   go-down


8. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • However, biased risk grouping and high treatment-related mortality have hampered some of those comparisons.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • The treatment protocol itself was identified as an independent risk factor.
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • Prospective trials are warranted to determine whether young adults would benefit from similar treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Prognosis. Survival Analysis. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Saşmaz I, Tanyeli A, Bayram I, Antmen B, Yilmaz L, Küçükosmanoğlu O, Kilinç Y: The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia. Turk J Pediatr; 2004 Jan-Mar;46(1):32-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia.
  • Anthracycline and cytosine arabinoside are used in combination as the standard therapy for remission induction of acute nonlymphoblastic leukemia.
  • Idarubicin, a synthetic daunorubicin analogue, shows an improved spectrum activity and diminishes acute or chronic toxicity when compared with the other anthracyclines.
  • This study has been carried out in our clinic in order to evaluate the efficiency of the acute nonlymphoblastic leukemia protocol which includes idarubicin.
  • Thirty-eight patients admitted to our Department between 1992-1999 and diagnosed as acute nonlymphoblastic leukemia (ANLL) were included in the study.
  • Induction therapy consisted of idarubicin plus cytosine arabinoside and etoposide.
  • Consolidation therapy consisted of two courses, followed by maintenance therapy with thioguanine, cytosine arabinoside, vincristine and cyclophoshamide.
  • We established that the protocol with idarubicin reached a higher remission ratio when compared with the other protocols with anthracycline.
  • However, the degree of the hematologic toxicity ratios related to the therapy increased the complication ratios, which affected the long-term life analyses directly.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Bone Marrow Examination. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Infant. Male. Methotrexate / administration & dosage. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15074372.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin; ANLL91 protocol
  •  go-up   go-down


10. da Costa Moraes CA, Trompieri NM, Cavalcante Felix FH: Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital. J Pediatr Hematol Oncol; 2008 May;30(5):387-90
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital.
  • Acute promyelocytic leukemia (APL) is an uncommon form of pediatric acute nonlymphocytic leukemia.
  • The introduction of all-transretinoic acid (ATRA) or tretinoin, a biologic response modifier, in its therapy was followed by dramatic improvement in its outcome.
  • To show the results of APL treatment in our hospital, we reviewed the information about 15 patients less than 18 years old, newly diagnosed with APL between November 2002 and November 2006.
  • The clinical charts were searched for data regarding clinical presentation, diagnosis, initial response with induction therapy, toxicity of ATRA, and antracyclic drug (daunorubicin).
  • Fourteen patients received induction chemotherapy.
  • There was a death owing to sepsis before the beginning of the therapy and 2 relapses with death associated with the therapy discontinuation.
  • Preliminary results are encouraging and confirm that ATRA is safe and efficacious as first choice therapy for APL.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Brazil. Female. Hospitals, Pediatric. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458575.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


11. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF: Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):387-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia.
  • BACKGROUND: Children with acute lymphocytic leukemia (ALL) are at high risk for developing hyperglycemia.
  • We hypothesized that children with ALL who become hyperglycemic during induction chemotherapy have an increased risk for infection during their first year of treatment.
  • PROCEDURE: We conducted a retrospective chart review of 135 patients diagnosed with ALL during 1999-2001 at Texas Children's Hospital.
  • Infectious outcomes during the first year of therapy were compared in three groups patients based on blood glucose concentrations during induction therapy: euglycemic (<140 mg/dl), mild hyperglycemic (MH) (140-199 mg/dl) and overt hyperglycemic (OH) (blood glucose >200 mg/dl).
  • Patients with MH and OH were 2.5 times (95% CI 1.0-6.2) and 2.1 times (95% CI 1.0-4.6) more likely to have documented infections, respectively.
  • Patients with OH were 4.2 times (95% CI 1.5-12) more likely to have bacteremia/fungemia, 3.8 times (95% CI 1.2-11.6) more likely to have cellulitis, and 4.0 times (95% CI 1.7-9.3) more likely to be admitted for fever and neutropenia than the euglycemia group.
  • CONCLUSION: Hyperglycemia, especially when overt, may be a previously unrecognized risk factor of infectious complications in children with ALL during the first year of treatment.
  • [MeSH-major] Hyperglycemia / complications. Infection / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18523991.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


12. Harris MB, Shuster JJ, Pullen J, Borowitz MJ, Carroll AJ, Behm FG, Camitta B, Land VJ: Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia; 2000 Sep;14(9):1570-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study.
  • Between May 1987 and January 1991, 1354 patients, 1-21 years old, with standard or poor prognosis B-lineage acute lymphocytic leukemia were treated on the Pediatric Oncology Group Study 8602.
  • After completion of intensification at week 25, all patients received the same maintenance therapy until 3 years from diagnosis.
  • Significant differences between treatments for CCR, testicular, CNS relapses overall or with regard to phenotype (pre-B vs early pre-B), gender, or race were not detected.
  • No significant differences in CCR were noted between patients with pre-B and early pre-B ALL (P = 0.22 stratified by risk group and treatment).
  • This study was unable to detect statistical difference between asparaginase (regimen B) and cytarabine (regimen C) during the intensification phase of therapy in children with B-lineage acute lymphocytic leukemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Double-Blind Method. Female. Humans. Infant. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10995002.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-35096
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


13. Moe PJ, Holen A, Nygaard R, Glomstein A, Madsen B, Hellebostad M, Stokland T, Wefring KW, Steen-Johnsen J, Nielsen B, Hapnes C, Børsting S: Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience. Pediatr Hematol Oncol; 2003 Apr-May;20(3):187-200
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.
  • This study included all 690 children in Norway diagnosed as having acute lymphocytic leukemia (ALL) from July 1975 till the end of 1997.
  • From 1992, systemic therapy was considerably intensified, and, in addition, patients in a subgroup of the high-risk and very high-risk groups were given prophylactic cranial irradiation.
  • The overall findings showed that MTX significantly reduced central nervous system (CNS)-related relapses, and, in general, reinforced systemic therapy reduced significantly non-CNS relapses and deaths.
  • Forty patients (6%) developed isolated CNS relapse, 27 (4%) had combined CNS relapse, whereas 180 (26%) had non-CNS relapse.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / prevention & control. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Cranial Irradiation. Drug Administration Schedule. Humans. Infant. Infusion Pumps. Injections, Spinal. Neoplasm Recurrence, Local. Norway / epidemiology. Prospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12637215.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Razzouk BI, Hockenberry M, Hinds PS, Rackoff W, Hord JD: A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):8527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy.
  • : 8527 Background: This study was designed to assess the effect of epoetin alfa (EPO) on hemoglobin (Hb) and quality of life (QOL) in children with cancer receiving myelosuppressive chemotherapy (CT).
  • METHODS: This was a double-blind, placebo (PBO)-controlled study of pts aged 5-18 y with malignant solid tumors (ST), Hodgkin's lymphoma (HL), acute lymphocytic leukemia (ALL), or non-Hodgkin's lymphoma (NHL) and Hb <12 g/dL.
  • Pts were stratified by tumor type (ST/HL or ALL/NHL) and randomized 1:1 to receive IV EPO 600 U/kg or PBO weekly for 16 wks.
  • Primary end point was pt-reported Peds Quality of Life Inventory (PedQL-I™) Total Score; secondary endpoints included parent-reported PedsQL-I and pt- and parent-reported PedsQL Cancer Module (PedsQL-CM: Cognitive Problems, Communication, Nausea, Pain and Hurt, Physical Appearance, Procedural Anxiety, Treatment Anxiety, Worry), Hb, and transfusions.
  • Pt- and parent-reported Cognitive Problems scores were improved in ALL/NHL pts receiving EPO vs PBO (P=.026 and P=.014, respectively), but no other PedsQL-CM domain.
  • CONCLUSIONS: IV EPO was well tolerated in pediatric cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lu Y, Sun LR, Pang XY, Lu ZH, Sui AH: [Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases]. Ai Zheng; 2007 Jan;26(1):54-7
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases].
  • This study was to detect EBV infection in pediatric leukemia, and to explore its clinical significance.
  • METHODS: EBV DNA in peripheral blood mononuclear cells in 35 pediatric leukemia patients, including 26 cases of acute lymphoblastic leukemia (ALL) (24 received initial treatment and 2 received retreatment), 8 cases of acute non-lymphocytic leukemia (ANLL) and 1 case of chronic lymphocytic leukemia (CLL), and in 14 healthy children was detected by fluorescent quantitative polymerase chain reaction (FQ-PCR).
  • Its clinical significance was analyzed according to the clinical manifestations, prednisone sensitivity test, and complete remission (CR) rate after induction chemotherapy.
  • RESULTS: EBV DNA was detected in 8 (22.86%) of the 35 pediatric leukemia patients.
  • The positive rate of EBV DNA was 26.92% (7/26) in ALL with quantity of (5.144+/-6.91)x10(5) copies/ml, and 12.5% (1/8) in ANLL patients with quantity of 4.031x10(3) copies/ml.
  • In ALL, the rate of no response to prednisone was significantly higher in the patients with EBV infection than in the patients without EBV infection (100% vs. 26.32%, P =0.001); CR rate after induction chemotherapy was significantly lower in the patients with EBV infection than in the patients without EBV infection (28.57% vs. 84.21%, P=0.003).
  • In ANLL, the differences of CR rate and relapse rate were not significant between the patients with and without EBV infection (P=0.5).
  • CONCLUSIONS: Pediatric leukemia patients with EBV infection have higher incidence of peripheral leukocytosis and hepatosplenomegaly.
  • [MeSH-major] Epstein-Barr Virus Infections. Leukemia, Myeloid, Acute / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Child. Child, Preschool. DNA, Viral / blood. Female. Hepatomegaly / etiology. Herpesvirus 4, Human / genetics. Humans. Infant. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / virology. Leukocytosis / etiology. Male. Prednisone / therapeutic use. Remission Induction. Splenomegaly / etiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222368.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / DNA, Viral; VB0R961HZT / Prednisone
  •  go-up   go-down


16. Hou Y, Hu Q, Liu AG, Zhang LQ, Liu SY: [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy]. Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr;8(2):101-4
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy].
  • This study aimed to investigate the expression of survivin and its location as well as the relationship between cellular location and expression of survivin and the therapeutic efficacy at the cellular level.
  • METHODS: The expression of survivin protein was detected by immunohistochemical assay in bone marrow cells from 62 children with acute leukemia and 40 hospitalized children who did not have leukemia (Control group), and in a human acute T lymphocytic leukemia cell line (Molt-4 cells) treated in vitro with daunorubicin (DNR).
  • RESULTS: Survivin protein was expressed in 41.9% of the 62 children with acute leukemia but in only 5.0% of the Control group (chi(2)=16.66; P < 0.01).
  • The expression rate of survivin was 46.2% in cytoplasm and 53.9% in nucleus in the children with acute leukemia (chi(2)0.3077; P> 0.05).
  • However, the remission rate of patients in whom survivin expression was seen in the nucleus was significantly higher than that in patients in whom survivin was expressed in cytoplasm after chemotherapy.
  • The survivin expression in Molt-4 cells decreased remarkably by DNR treatment in a time and dosage-dependent manner.
  • DNR treatment also induced survivin transllocation from cytoplasm to nucleus and cell apoptosis in a time and dosage-dependent manner.
  • CONCLUSIONS: Survivin may play an important role in the development and prognosis of childhood acute leukemia.
  • The different expression pattern of survivin in the cytoplasm and the nucleus may be associated with therapeutic efficacy and prognosis in acute leukemia.
  • [MeSH-major] Bone Marrow Cells / chemistry. Daunorubicin / therapeutic use. Leukemia, Myeloid, Acute / metabolism. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Apoptosis / drug effects. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613699.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


17. Zhang JB, Sun Y, Dong J, Liu LX, Ning F: [Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance]. Ai Zheng; 2005 Aug;24(8):1015-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance].
  • BACKGROUND & OBJECTIVE: Previous studies revealed that lung resistance protein (LRP) and multidrug resistance-associated protein (MRP) relate to drug resistance of childhood leukemia, which is not caused by only one mechanism.
  • This study was to evaluate the expression of LRP and MRP genes in childhood leukemia and their correlation.
  • METHODS: The expression of LRP and MRP in 38 children with acute leukemia and 6 healthy children were measured with reverse transcription-polymerase chain reaction (RT-PCR); their clinical significance was analyzed according to complete remission (CR) rate of the patients after chemotherapy.
  • The positive rate of LRP was significantly lower in acute lymphoblastic leukemia (ALL) than in acute nonlymphocytic leukemia (ANLL) [18.5% (5/27) vs. 45.5% (6/11), P < 0.05]; however, the positive rate of MRP was 59.3% (16/27) in ALL, and 45.5% (5/11) in ANLL (P > 0.05).
  • CONCLUSION: Childhood acute leukemia patients with overexpression of LRP and MRP suffer severe disease and achieve low remission rateû lower remission rate of childhood ANLL patients may relate to LRP expression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / metabolism. Multidrug Resistance-Associated Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086885.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


18. Adderson EE: Histoplasmosis in a pediatric oncology center. J Pediatr; 2004 Jan;144(1):100-6
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histoplasmosis in a pediatric oncology center.
  • OBJECTIVE: To understand the presentation and current management of histoplasmosis in a pediatric oncology center.
  • RESULTS: Between 1988 and 2001, 57 patients with cancer had 61 episodes of acute histoplasmosis.
  • Of these, 76% were male, and 64% had acute lymphocytic leukemia (ALL).
  • The most rapid and specific tests for histoplasmosis in patients with cancer were histopathologic examination of lung biopsy specimens in patients with localized pulmonary infection and Histoplasma sp. antigen detection in the urine of patients with disseminated histoplasmosis (DH).
  • The mean times to diagnosis were 20.6+/-15.2 days (pulmonary) and 18.6+/-8.2 days (disseminated) after the onset of symptoms.
  • Most patients were treated with amphotericin B (AmB) followed by azole drugs for a mean of 8.5+/-3.1 weeks (pulmonary) and 10.4+/-7.9 weeks (disseminated).
  • No patient died of histoplasmosis, but cancer therapy often was modified because of the infection.
  • Most received unnecessary antibacterial drugs.
  • No deaths were attributed to histoplasmosis; outcomes after treatment are good.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Child. Female. Humans. Lung Diseases, Fungal / complications. Lung Diseases, Fungal / diagnosis. Lung Diseases, Fungal / drug therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Histoplasmosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14722526.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


19. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, Stigter RL, van Wering ER, Janka-Schaub GE, Slater R, Pieters R: Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood; 2003 Apr 1;101(7):2743-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL.
  • The (12;21) translocation resulting in TEL/AML1 gene fusion is present in about 25% of childhood precursor B-lineage acute lymphoblastic leukemia (ALL) and is associated with a good prognosis and a high cellular sensitivity to L-asparaginase (L-Asp).
  • Real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis surprisingly revealed that 30 patients positive for t(12;21) expressed 5-fold more AS mRNA compared with 17 patients negative for t(12;21) (P =.008) and 11 samples from healthy controls (P =.016).
  • We conclude that the sensitivity of t(12;21)(+) childhood ALL to L-Asp is not associated with the expression level of the AS gene.
  • [MeSH-major] Asparaginase / pharmacology. Aspartate-Ammonia Ligase / analysis. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 21. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Translocation, Genetic
  • [MeSH-minor] Case-Control Studies. Child. Child, Preschool. Humans. Infant. RNA, Messenger / analysis. Up-Regulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12433682.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


20. Kreitman RJ: Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des; 2009;15(23):2652-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
  • Recombinant immunotoxins which have been tested in patients with chemotherapy-pretreated hematologic malignancies include LMB-2 (anti-CD25), BL22 (CAT-3888, anti-CD22) and HA22 (CAT-8015, anti-CD22), each containing an Fv fragment fused to truncated Pseudomonas exotoxin.
  • Major responses were observed with LMB-2 in adult T-cell leukemia, chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, Hodgkin's disease, and hairy cell leukemia (HCL).
  • HA22, an improved version of BL22 with higher affinity to CD22, is now undergoing phase I testing in HCL, CLL, non-Hodgkin's lymphoma, and pediatric acute lymphoblastic leukemia.
  • [MeSH-major] Drug Discovery / methods. Drug Resistance, Neoplasm / drug effects. Hematologic Neoplasms / drug therapy. Immunotoxins / therapeutic use. Recombinant Proteins / therapeutic use

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689336.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Immunotoxins; 0 / Leukocidins; 0 / Pseudomonas aeruginosa Cytotoxins; 0 / Recombinant Proteins; 0 / Toxins, Biological
  • [Number-of-references] 190
  •  go-up   go-down


21. Sternberg A: Clofarabine. Bioenvision/ILEX. Curr Opin Investig Drugs; 2003 Dec;4(12):1479-87
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clofarabine is a purine nucleoside antimetabolite under development by Bioenvision (under license from the Southern Research Institute) and ILEX for the potential treatment of solid tumors, acute myelogenous leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia.
  • In September 2003, Bioenvision initiated a phase II trial in Europe in pediatric acute lymphoblastic leukemia, and in October 2003, ILEX submitted the first part of a rolling NDA to the FDA for the treatment of acute leukemia in children.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Drugs, Investigational / therapeutic use. Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14763136.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / Drugs, Investigational; 762RDY0Y2H / clofarabine
  • [Number-of-references] 64
  •  go-up   go-down


22. Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G: Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc Health Risk Manag; 2008;4(4):825-36
MedlinePlus Health Information. consumer health - Metabolic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease.
  • Some pediatric disease states are at risk for premature cardiovascular disease, with clinical coronary events occurring very early in adult life.
  • Survivors of specific pediatric cancer groups, particularly acute lymphocytic leukemia, central nervous system tumors, sarcomas, lymphomas, testicular cancer, and following bone marrow transplantation, may develop metabolic syndrome traits due to: hormonal deficiencies (growth hormone deficiency, thyroid dysfunction, and gonadal failure), drug or radiotherapy damage, endothelial impairment, physical inactivity, adipose tissue dysfunction, and/or drug-induced magnesium deficiency.
  • [MeSH-major] Cardiovascular Diseases / prevention & control. Metabolic Syndrome X / drug therapy. Neoplasms / therapy. Survivors
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Bone Marrow Transplantation / adverse effects. Child. Humans. Radiotherapy / adverse effects. Risk Assessment. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma Myeloma. 2005 Sep;6(2):122-30 [16231850.001]
  • [Cites] J Diabetes Complications. 2006 Mar-Apr;20(2):121-32 [16504841.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Feb;19(2):121-7 [16562584.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1109-17 [16699534.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):890-6 [16818852.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1793-801 [16823477.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] Cancer Treat Rev. 2002 Aug;28(4):195-214 [12363460.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):611-6 [12574189.001]
  • [Cites] Rev Endocr Metab Disord. 2003 Mar;4(1):23-32 [12618557.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4401-7 [16954158.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Nov;18(9):710-8 [17100159.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Dec;17(6):475-86 [17118696.001]
  • [Cites] Circulation. 2006 Dec 12;114(24):2710-38 [17130340.001]
  • [Cites] Pediatr Diabetes. 2006 Dec;7(6):311-21 [17212598.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 May;29(5):309-14 [17483708.001]
  • [Cites] Acta Oncol. 2007;46(4):480-9 [17497315.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2059-61 [17586288.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1356-63 [17627001.001]
  • [Cites] Eur J Endocrinol. 2000 Aug;143(2):243-50 [10913944.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Endocr Rev. 2000 Dec;21(6):697-738 [11133069.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2775-8 [11397886.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5245-51 [11701685.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7 [12912790.001]
  • [Cites] Endocr Pract. 2003 May-Jun;9(3):237-52 [12924350.001]
  • [Cites] Diabetes Care. 2003 Nov;26(11):3160-7 [14578255.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5227-31 [14602754.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):185-9 [14654924.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):81-6 [14715831.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):108-13 [14715836.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):433-8 [14744958.001]
  • [Cites] Arch Intern Med. 2004 May 24;164(10):1066-76 [15159263.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2362-74 [15175438.001]
  • [Cites] Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 [15286277.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5003-12 [15472198.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2494-7 [15477412.001]
  • [Cites] Diabetes. 1988 Dec;37(12):1595-607 [3056758.001]
  • [Cites] Pediatrics. 1992 Mar;89(3 Pt 2):525-84 [1538956.001]
  • [Cites] BMJ. 1995 Jul 15;311(6998):171-4 [7613432.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] Pediatrics. 1996 Oct;98(4 Pt 1):649-58 [8885941.001]
  • [Cites] Eur J Endocrinol. 1998 Jan;138(1):89-91 [9461323.001]
  • [Cites] Diabet Med. 1998 Jul;15(7):539-53 [9686693.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Dec;22(12):1145-58 [9877249.001]
  • [Cites] Prev Med. 1998 Nov-Dec;27(6):879-90 [9922071.001]
  • [Cites] Diabet Med. 1999 May;16(5):442-3 [10342346.001]
  • [Cites] J Pediatr Endocrinol Metab. 2004 Oct;17(10):1405-13 [15526719.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):480-7 [17630615.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):529-34 [17762493.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3816-21 [17652222.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Nov;29(11):776-82 [17984698.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):341-6 [17918262.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):462-7; discussion 468 [18064658.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s817-9 [18265474.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s820-2 [18265475.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s867-71 [18265480.001]
  • [Cites] Cancer. 2000 May 1;88(9):2116-21 [10813724.001]
  • [Cites] Diabetes Care. 2000 Mar;23(3):381-9 [10868870.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Dec;61(6):683-91 [15579181.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):589-602 [15613441.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(2):209-10 [15558043.001]
  • [Cites] Metabolism. 2005 Mar;54(3):321-9 [15736109.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2659-65 [15713715.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3718-25 [15738540.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Sep;27(9):499-501 [16189445.001]
  • (PMID = 19065999.001).
  • [ISSN] 1176-6344
  • [Journal-full-title] Vascular health and risk management
  • [ISO-abbreviation] Vasc Health Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2597761
  •  go-up   go-down


23. Rice SC, Vacek PM, Homans AH, Kendall H, Rivers J, Messier T, Finette BA: Comparative analysis of HPRT mutant frequency in children with cancer. Environ Mol Mutagen; 2003;42(1):44-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To gain insight into somatic mutational mechanisms in children who develop cancer, we determined the background mutant frequency (Mf) in the hypoxanthine phosphoribosyl transferase (HPRT) reporter gene of peripheral blood lymphocytes from pediatric cancer patients at the time of diagnosis and prior to therapeutic intervention.
  • We studied 23 children with hematologic malignancies and 31 children with solid tumors prior to initial therapeutic intervention.
  • Children with solid tumors, specifically sarcomas, and Hodgkin's disease were significantly older and had elevated HPRT Mfs (6.1 x 10(-6) and 3.7 x 10(-6), respectively) at the time of diagnosis, compared to normal controls (2.3 x 10(-6)) and other pediatric tumor groups including children with acute lymphocytic leukemia and non-Hodgkin's lymphoma (ALL/NHL, 1.7 x 10(-6)), central nervous system tumors (CNS, 3.6 x 10(-6)), and neuroblastoma (1.9 x 10(-6)).
  • In addition, these data demonstrate the importance of correcting for the effect of age when comparing the frequency of somatic mutations in children and should provide baseline data for future longitudinal biomonitoring studies on the genetic effects of chemotherapy in children treated for cancer.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12874812.001).
  • [ISSN] 0893-6692
  • [Journal-full-title] Environmental and molecular mutagenesis
  • [ISO-abbreviation] Environ. Mol. Mutagen.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 1F32ES058701ZRG4; United States / NCI NIH HHS / CA / 1K01CA77737; United States / NICHD NIH HHS / HD / 1K11HD01010; United States / NICHD NIH HHS / HD / 1R29HD35309-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


24. Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, Emmerich B, Stockmeyer B, Lang P, Beck JD, Fey GH: A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia; 2007 Jul;21(7):1405-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is present at high surface density on chronic B-lymphocytic leukemia (B-CLL) cells and cells of other B-cell malignancies, and is a prime target for therapy with antibody-derived agents.
  • Many attempts have been made to target malignant cells via CD19, but to date none of these agents have received drug approval.
  • This fusion protein induced efficient antigen-restricted apoptosis of several human leukemia- and lymphoma-derived cell lines including Nalm-6, which it eliminated at an effective concentration (EC(50)) of 2.5 nM.
  • It induced apoptosis of primary malignant cells in 12/12 samples from B-CLL patients, including patients responding poorly to fludarabine, and of cells from one pediatric acute lymphoblastic leukemia patient.
  • [MeSH-major] Antigens, CD19 / drug effects. Apoptosis / drug effects. Immunotoxins / pharmacology. Leukemia, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Animals. Drug Evaluation, Preclinical. Drug Synergism. Exotoxins. Humans. Immunoglobulin Fragments. Mice. Mice, SCID. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Pseudomonas. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / therapeutic use. Survival Rate. Tumor Burden / drug effects. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495978.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Exotoxins; 0 / Immunoglobulin Fragments; 0 / Immunotoxins; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


25. Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist; 2001;6 Suppl 2:22-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The National Cancer Institute is working cooperatively with research centers across the U.S. to evaluate its clinical activity in hematologic malignancies, such as acute promyelocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma.
  • The safety and pharmacokinetics of arsenic trioxide are also being evaluated in pediatric patients with refractory leukemia and lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Clinical Trials as Topic. Hematologic Neoplasms / drug therapy. Oxides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331437.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 27
  •  go-up   go-down


26. Talano JM, Casper JT, Camitta BM, Keever-Taylor CA, Murray KJ, Eapen M, Pierce KL, Margolis DA: Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. Bone Marrow Transplant; 2006 Jan;37(2):135-41
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) have only a 20% event-free survival when treated with chemotherapy alone.
  • Four developed grades III-IV acute GVHD.
  • Three of 24 evaluable patients developed extensive chronic GVHD.
  • Five of six patients in >CR2 or relapse at the time of transplant died.
  • [MeSH-major] Bone Marrow Transplantation. Donor Selection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273115.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down






Advertisement